Financial Survey: Pear Therapeutics (NASDAQ:PEAR) and DCC (OTCMKTS:DCCPF)

Pear Therapeutics (NASDAQ:PEARGet Rating) and DCC (OTCMKTS:DCCPFGet Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Pear Therapeutics and DCC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pear Therapeutics N/A -289.70% -32.24%
DCC N/A N/A N/A

Volatility & Risk

Pear Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, DCC has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

53.7% of Pear Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Pear Therapeutics and DCC’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pear Therapeutics $4.21 million 89.88 -$65.14 million N/A N/A
DCC $24.23 billion N/A $426.64 million N/A N/A

DCC has higher revenue and earnings than Pear Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and price targets for Pear Therapeutics and DCC, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pear Therapeutics 0 1 4 0 2.80
DCC 1 1 2 0 2.25

Pear Therapeutics currently has a consensus price target of $11.75, indicating a potential upside of 328.83%. Given Pear Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Pear Therapeutics is more favorable than DCC.

Summary

DCC beats Pear Therapeutics on 5 of the 9 factors compared between the two stocks.

About Pear Therapeutics (Get Rating)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

About DCC (Get Rating)

DCC plc provides sales, marketing, and support services worldwide. The company's DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants, and natural gas. This segment serves approximately 0.9 million customers. Its DCC Retail & Oil segment markets, sells, and retails transport and commercial fuels, heating oils, and related products and services; operates retail petrol stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and filling, and outbound logistics services. This segment serves domestic, agricultural, commercial/industrial, forecourt, aviation, and marine customers. The company's DCC Healthcare segment offers products and services to healthcare providers, and health and beauty brand owners; outsourced contract manufacturing services to the health and beauty sector; nutrition products, such as vitamins and health supplements; beauty products; and product development, formulation, manufacturing, and packaging services. In addition, this segment procures and sells exempt medicinal products. Its DCC Technology segment distributes consumer technology products, including smart home products, gaming consoles, peripherals and software, wearable technology, and accessories; business and enterprise technology products, such as tablets, notebooks, and PCs; networking and security products; communication products comprising smartphones, feature phones, accessories, and unified communication products; and servers and storage products, audio visual products, printers, peripherals, cables and connectors, and consumables to retailers, resellers, and integrators. It also provides supply chain services. DCC plc was founded in 1976 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.